Themis MedicareNSE:THEMISMED -2.64%74 Net Margin % is 11.61% as of Mar. 2026, which is 22% above its 10-year median of 9.50. GuruFocus rates NSE:THEMISMED with a GF Score™ of 74/100 and a GF Value™ of ₹149.53 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Themis Medicare ranks worse than 66.25% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Themis Medicare's Net Income for the
three
months ended in Mar. 2026 was ₹89 Mil. Themis Medicare's Revenue for the
three
months ended in Mar. 2026 was ₹765 Mil. Therefore, Themis Medicare's net margin for the quarter that ended in Mar. 2026 was 11.61%.
The historical rank and industry rank for Themis Medicare's Net Margin % or its related term are showing as below:
NSE:THEMISMED'
s Net Margin % Range Over the Past 10 Years
Min: -5.88 Med: 9.5 Max: 18.62
Current: 0.33
NSE:THEMISMED's Net Margin % is ranked worse than 66.25% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs NSE:THEMISMED: 0.33
Themis Medicare (NSE:THEMISMED) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Themis Medicare Net Margin % Related Terms
Themis Medicare Net Margin % Historical Data
* Premium members only.
The historical data trend for Themis Medicare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THEMISMED vs ZTS, UTHR: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Themis Medicare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Themis Medicare (NSE:THEMISMED) has a Net Margin % of 11.61% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Themis Medicare and its competitors. This is 22% above median its historical median of 9.50. According to the industry distribution chart, Themis Medicare ranks #632 out of 954 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Themis Medicare's Net Margin % too high?
Themis Medicare's current Net Margin % of 11.61% is 22% above median its 10-year median of 9.50. The Drug Manufacturers industry median Net Margin % is 5.70. Themis Medicare's value of 11.61% is 103.9% above this industry median. Based on the distribution chart, Themis Medicare ranks #632 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Themis Medicare has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #632 out of 954 companies for Net Margin %. This places Themis Medicare in the lower half of its industry. The industry median Net Margin % is 5.70. Themis Medicare's value of 11.61% is 103.9% above this benchmark. While the company's 10-year median is 9.50 vs. the industry median of 5.70, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current Net Margin % of 11.61% is 103.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current Net Margin % is 11.61%, which is 22% above median its own 10-year median of 9.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (NSE:THEMISMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.53, compared to a current price of ₹109.55 — trading 26.7% below its estimated fair value. The current Net Margin % is 11.61%, which is 22% above median its 10-year median of 9.50 and 103.9% above the Drug Manufacturers industry median of 5.70. Themis Medicare's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Themis Medicare (NSE:THEMISMED), the current Net Margin % is 11.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (NSE:THEMISMED) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹109.55 is trading 26.7% below its estimated GF Value™ of ₹149.53.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for NSE:THEMISMED:
Net Margin %: 11.61% (22% above median its 10-year median of 9.50)
GF Value™: ₹149.53 vs. price of ₹109.55 (26.7% below fair value)
Industry Position: 103.9% above the Drug Manufacturers median (#632 of 954)
No single metric tells the full story. See the NSE:THEMISMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
74GF Score
Get the complete analysis for NSE:THEMISMED
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THEMISMED has been successfully added to your 
